This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo). (December 2016)
Record Type:
Journal Article
Title:
Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo). (December 2016)
Main Title:
Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)